Yonah S. Tehrani: CDT vs Anticoagulation in Intermediate High Risk PE – The PRAGUE-26 Trial
Yonah S. Tehrani, Physician at Shaare Zedek Medical Center, Jerusalem, shared a post on LinkedIn:
“PRAGUE-26 (NEJM, Aug 31, 2026) tested a question most PE pathways still leave to local culture: in intermediate-high–risk pulmonary embolism, does catheter-directed thrombolysis change early outcomes versus anticoagulation alone?
In 558 randomized patients, the 7-day composite of death, recurrent PE, or cardiorespiratory decompensation fell from 6.8% to 0.7% (RR 0.10).
The signal was decompensation, not a large mortality difference.
Clinically relevant and major bleeding rates were similar; two intracranial hemorrhages occurred with CDT.
For health systems this is less a device story than an operations story.
Benefit only exists if PERT, IR/cath lab, and ICU can mobilize without delay – and if selection stays tight.
A 7-day, partly clinician-defined endpoint in an open-label trial should inform pathways, not automatic escalation.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 18:12Adil Nawaz: Extended Dual Antiplatelet Therapy After Coronary Stenting
-
Oct 16, 2026, 17:50Elad Asher։ STORM-PE Shows Functional Benefits of Thrombectomy
-
Oct 16, 2026, 17:32Shruthi Narayan: STORM-PE and STRIKE-PE Studies Advance Understanding of Recovery After Pulmonary Embolism
-
Oct 16, 2026, 17:22Wolfgang Miesbach։ What a Near-Perfect FISH Score Fails to See
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke
-
Oct 16, 2026, 17:03Only 5 Days Left to Submit Your Research for EAHAD 2027
-
Oct 16, 2026, 16:48Abdul Rahman: Reticulocyte Count and Bone Marrow Activity
-
Oct 16, 2026, 16:44DOAC Adherence in Stroke Patients With Atrial Fibrillation – International Journal of Stroke
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand